Cholangiocarcinoma News

Efficacy and Safety of Futibatinib in iCCA Harboring FGFR2 Fusions/Rearrangements: Updated Results of the FOENIX-CCA2 Trial

September 2022, Vol 3, No 3

Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements. At data cutoff (October 1, 2020) of the primary analysis, an objective response rate (ORR) of 41.7% was reported with a median duration of response (DOR) of 9.7 months.1 With an additional 8 months of follow-up, final analysis results including efficacy and safety data of the trial were recently reported at the 2022 ASCO annual meeting.

The FOENIX-CCA2 study enrolled patients with advanced/metastatic iCCA with an FGFR2 fusion/rearrangement and progressive disease after ≥1 prior treatments, including gemcitabine plus platinum-based chemotherapy. Eligible patients received 20 mg of futibatinib once daily until progressive disease or intolerability. The primary end point was ORR by independent central review; secondary end points were DOR, disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and patient-reported outcomes. The data cutoff date was May 29, 2021.

A total of 103 patients were enrolled in the study. The median age of the study population was 58 years; the majority were female (56%), had received ≥2 prior treatments (53%), and harbored FGFR2 fusions (78%). At data cutoff, 96 of the 103 patients (93%) had discontinued treatment. The median number of treatment cycles was 13 for a median treatment duration of 9.1 months.

At a median follow-up of 25 months, the confirmed ORR was 41.7% (1 complete response [CR], 42 partial responses [PRs]) and DCR was 82.5% (1 CR, 42 PRs, 42 stable disease), which was the same as previously reported in the primary analysis. The median DOR was 9.5 months, and median time to response was 2.6 months. Median PFS was 8.9 months, with a 12-month PFS rate of 35.4%. Mature median OS was 20.0 months, with a 12-month OS rate of 73.1%.

No new safety signals were identified. Common treatment-related adverse events (TRAEs) included hyperphosphatemia (85%), alopecia (33%), dry mouth (30%), diarrhea (28%), dry skin (27%), and fatigue (25%). Treatment discontinuation due to TRAEs was reported in 4 patients. No treatment-related deaths occurred.

Quality-of-life (QOL) assessments were performed using the EuroQoL visual analog scale, and QOL was maintained from baseline to 9 months (treatment cycle 13).

Goyal and colleagues found that the results of the final analysis of FOENIX-CCA2 were consistent with those of the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in previously treated patients with advanced/metastatic iCCA harboring FGFR2 fusion/rearrangements. The authors noted that the mature OS data far exceeded historical data in this patient population.

Reference

  1. 1. Goyal L, Meric-Bernstam F, Hollebecque A, et al. Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1–4 inhibitor futibatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements. American Association for Cancer Research Annual Meeting 2021. Presentation CT010.

Source: Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. Abstract 4009.

Related Items

Using Liquid Biopsy to Detect FGFR2 and Other Actionable Rearrangements in Patients With GI Cancer
September 2023, Vol 4, No 3
At the 2023 ASCO meeting, Pashtoon Kasi, MD, MS, presented results from the study Liquid-Biopsy Detection of FGFR2 and Other Actionable Rearrangements in GI Malignancies, with the aim to demonstrate the utility of ctDNA-based comprehensive genomic profiling (CGP) to detect REs in patients—in particular, patients with GI malignancies.
CCA Summit Live from ASCO 2023
By Renuka V. Iyer, MD; Vaibhav Sahai, MBBS, MS
Videos
On June 4, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO).
GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.
Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA: NEO-GAP
September 2022, Vol 3, No 3
For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence.
Toripalimab Combined with Gemcitabine and S-1 in the First-Line Treatment of Advanced BTCs
September 2022, Vol 3, No 3
Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal.
PROs with Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Regional Subgroup Analysis of Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
September 2022, Vol 3, No 3
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Adjuvant GemCis versus CAP in Patients with Resected Lymph Node–Positive eCCA: The STAMP Study
September 2022, Vol 3, No 3
Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
CCA Summit Live from ASCO 2022
By Ghassan K. Abou-Alfa, MD, MBA
Videos
Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: